Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12764041 | 1.00 | REN (1.00) | RENKCNH2CYP3A4 | |
| SCHEMBL1518503 | 1.00 | REN (1.00) | RENKCNH2CYP3A4 | |
| SCHEMBL1518506 | 1.00 | REN (1.00) | RENKCNH2CYP3A4 | |
| SCHEMBL1518507 | 1.00 | REN (1.00) | RENKCNH2CYP3A4 | |
| SCHEMBL12837411 | 0.91 | REN (1.00) | RENKCNH2CYP3A4 | |
| SCHEMBL1518595 | 0.91 | REN (1.00) | RENKCNH2CYP3A4 | |
| SCHEMBL12764040 | 0.91 | REN (1.00) | RENKCNH2CYP3A4 | |
| SCHEMBL1518599 | 0.91 | REN (1.00) | RENKCNH2CYP3A4 | |
| SCHEMBL1518596 | 0.91 | REN (1.00) | RENKCNH2CYP3A4 | |
| SCHEMBL12764367 | 0.90 | REN (0.82) | RENKCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053940-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-03-03 | — | — | US | disclosed |
| WO-2009135299-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053940-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | REN, ACE, ACE2 | REN 1/4885KCNH2 320/4885CYP3A4 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.